|
Delayed
Nasdaq
22:06:56 16/11/2026 +04
|
5-day change | 1st Jan Change | ||
| 9.305 USD | -0.91% |
|
+2.37% | +39.13% |
| 11-11 | Harvard Bioscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026 | CI |
| 11-10 | Harvard Bioscience, Inc., Q3 2026 Earnings Call, Nov 10, 2026 |
Company Valuation: Harvard Bioscience, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 287.7 | 115.4 | 228.4 | 92.03 | 29.81 | 42.94 | - | - |
| Change | - | -59.89% | 97.92% | -59.7% | -67.6% | 44.03% | - | - |
| Enterprise Value (EV) | 287.7 | 115.4 | 228.4 | 92.03 | 29.81 | 42.94 | 42.94 | 42.94 |
| Change | - | -59.89% | 97.92% | -59.7% | -67.6% | 44.03% | 0% | 0% |
| P/E | -705x | -12x | -66.9x | -7.54x | -0.52x | -4.31x | -16.1x | 21.8x |
| PBR | 3.65x | 1.64x | 3.18x | 1.47x | 2.16x | 8.54x | 13.8x | - |
| PEG | - | -0x | 1x | -0x | -0x | 0.1x | 0.2x | -0x |
| Capitalization / Revenue | 2.42x | 1.02x | 2.03x | 0.98x | 0.34x | 0.48x | 0.45x | 0.43x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 0.48x | 0.45x | 0.43x |
| EV / EBITDA | 0x | 0x | 0x | 0x | 0x | 5.37x | 4.57x | - |
| EV / EBIT | 0x | 0x | 0x | 0x | 0x | 7.16x | 4.77x | - |
| EV / FCF | 0x | -0x | 0x | -0x | 0x | -12.6x | 22.7x | 5.22x |
| FCF Yield | 0.02% | -0.38% | 5.36% | -1.31% | 18.3% | -7.92% | 4.4% | 19.2% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.1 | -2.3 | -0.8 | -2.8 | -12.8 | -2.177 | -0.5833 | 0.43 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 118.9 | 113.3 | 112.2 | 94.14 | 86.55 | 90.09 | 94.8 | 101 |
| EBITDA 1 | 18.5 | 10.84 | 14.55 | 7.196 | 8.081 | 8 | 9.4 | - |
| EBIT 1 | 16.72 | 9.497 | 13.11 | 5.294 | 6.163 | 6 | 9 | - |
| Net income 1 | -0.288 | -9.516 | -3.415 | -12.4 | -56.7 | -9.915 | -2.765 | 2.335 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 70.500 | 27.700 | 53.500 | 21.100 | 6.688 | 9.390 | 9.390 | 9.390 |
| Nbr of stocks (in thousands) | 4,081 | 4,166 | 4,269 | 4,362 | 4,458 | 4,573 | - | - |
| Announcement Date | 08/03/22 | 09/03/23 | 07/03/24 | 12/03/25 | 12/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
| -4.31x | - | - | - | 42.75M | ||
| 35.85x | 6.11x | 23.34x | 0.26% | 259B | ||
| 37.05x | 7.03x | 22x | 0.62% | 164B | ||
| 51.3x | 12.39x | 26.59x | -.--% | 154B | ||
| 18.11x | 3.57x | 11.61x | -.--% | 64.27B | ||
| 46.2x | 8.53x | 26.92x | -.--% | 61.61B | ||
| 21.52x | 2.56x | 12.9x | 2.35% | 53.94B | ||
| 33.9x | 6.72x | 22.81x | 0.59% | 49.04B | ||
| 46.16x | 11.32x | 24.94x | -.--% | 48.82B | ||
| 133.27x | 7.6x | 23.09x | -.--% | 45.24B | ||
| Average | 41.90x | 7.31x | 21.58x | 0.42% | 90B | |
| Weighted average by Cap. | 42.64x | 7.51x | 22.48x | 0.36% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- HBIO Stock
- Valuation Harvard Bioscience, Inc.
Select your edition
All financial news and data tailored to specific country editions
















